## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization

International Bureau



# 

(43) International Publication Date 12 February 2004 (12.02.2004)

PCT

## (10) International Publication Number WO 2004/013087 A1

(51) International Patent Classification7: C07C 233/87, C07D 307/78, 333/50, A61K 31/166, 31/381, 31/343

(21) International Application Number:

PCT/IB2003/002922

(22) International Filing Date: 23 July 2003 (23.07.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: TO2002A000674

fuly 2002 (26.07.2002)

(71) Applicant (for all designated States except US): ROTTA RESEARCH LABORATORIUM S.p.A. [IT/IT]; Galleria Unione 5, I-20122 Milano (IT).

(72)\Inventors; and

- Inventors/Applicants (for US only): (75) VMAKOVEC, Francesco [IT/IT]; Via Silvio Pellico, 14, I-20050 Lesmo (IT)/ VARNAVAS, Antonio [IT/IT]; Via Besenghi, 19, I-34143 Trieste (IT). LASSLANI, Lucia [IT/IT]; Via Besenghi, 19, I-34143 Trieste (IT). ROVATI, Lucio Claudio [IT/IT]; Via Ramazzotti, 1, I-20052 Monza (IT).
- (74) Agent: RAMBELLI, Paolo; Jacobacci & Partners SpA, Corso Regio Parco, 27, I-10152 Torino (IT).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,

SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Declarations under Rule 4.17:**


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT. RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTHRANYL DERIVATIVES HAVING AN ANTICHOLECYSTOKININ ACTIVITY (ANTI-CCK-1), A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL USE THEREOF



(57) Abstract: Anthranylic compounds having anti-CCK activity of general formula (I) in which, n is a whole number lying between 0 and 7; R1 is chosen independently from the groups ( $\Pi$ ), in which  $X_1$  is chosen independently from, S, O, NR<sub>2</sub> and X<sub>2</sub> is a group chosen from: H, C<sub>1</sub>-C<sub>4</sub> alkyl, F, Cl, CF<sub>3</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CN; R<sub>2</sub> is chosen from H or CH<sub>3</sub>; R<sub>3</sub> is chosen from H, CH<sub>3</sub>, F, Cl, CF<sub>3</sub>, OCH<sub>3</sub>; R<sub>4</sub> is chosen from the groups: H,  $-S-(CH_2)m-R_5$ ,  $-SO_2-(CH_2)m-R_5$  (n different from 0), a branched alkyl group, a cyclo alkyl, a cyclo alkenyl, the group 1 or 2 adamantile, a phenyl group optionally substituted; R<sub>5</sub> is chosen from the groups: H, linear or branched alkyl, cyclo alkyl, the group 1 or 2 adamantile, a suitably substituted phenyl group.

WO 2004/013087

## INTERNATIONAL SEARCH REPORT

	: SEARCH REPORT		PCT/I 02922	
A. CLASSI IPC 7	CO7C233/87 CO7D307/78 CO7D333 A61K31/343	3/50 A61K31/	'166 A61K	31/381
According to International Patent Classification (IPC) or to both national classification and IPC				
	S SEARCHED			
IPC 7	ocumentation searched (classification system followed by classification CO7C CO7D A61K A61P	allon symbols)		
Documentat	ation searched other than minimum documentation to the extent that	t such documents are inch	uded in the fields s	earched
Electronic d	data base consulted during the international search (name of data b	base and, where practical	, search terms used	j)
CHEM A	ABS Data, BEILSTEIN Data, EPO-Intern	nal, WPI Data,	PAJ, BIOS	IS, EMBASE
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the n	relevant passages	1	Relevant to claim No.
P,X	VARNAVAS, ANTONIO ET AL: "Anthracid derivatives: a new class of non-peptide CCK1 receptor antago BIOORGANIC & MEDICINAL CHEMISTRY vol. 11, no. 5, 6 March 2003 (20 pages 741-751, XP002265140 the whole document	f onists" / .		1–12
A	VARNAVAS, A. ET AL: "Synthesis of N-terminal substituted anthranilic acid dimer derivatives for evaluation on CCK receptors"  FARMACO, vol. 56, no. 8, 1 August 2001 (2001-08-01), pages 555-564, XP002265141 the whole document		1-12	
X Furth	her documents are listed in the continuation of box C.	Patent family	members are listed	in ann ex.
*Your document defining the general state of the art which is not considered to be of particular relevance invention of filling date or priority date and not in conflict with the application but determined the principle or theory underlying the invention of the carrier document but published on or after the international filling date invention.  *Your document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  *O' document referring to an oral disclosure, use, exhibition or other means  *P' document published prior to the International filing date but later than the priority date claimed  *Your document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone when the comment is combined with one or more other such document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  *X' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  *X' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  *X' document member of the same patent family				
16 December 2003 05/01			•	
Name and n	mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL — 2280 HV Rijswijk  Tel. (+31-70) 340—2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340—3016	Authorized officer  Goetz,		

### INTERNATIONAL SEARCH REPORT

PCT/IB 02922

C.(Continuation) DCCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Α VARNAVAS, ANTONIO ET AL: "Synthesis of 1-12 new anthranilic acid dimer derivatives and their evaluation on CCK receptors" FARMACO , vol. 55, no. 5, 2000, pages 369-375, XP002265142 the whole document